CompletedPhase 3NCT02063022
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Studying Extraskeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Italian Sarcoma Group
- Principal Investigator
- Roberto Luksch, MDItalian Sarcoma Group
- Intervention
- Standard treatment (as per protocol ISG SSG III)(drug)
- Enrollment
- 278 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2009 – 2022
Study locations (14)
- Centro di Riferimento Oncologico - Unit of Medical Oncology, Aviano, Pordenone, Italy
- I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
- IRCCS materno infantile Burlo Garofolo, Trieste, T, Italy
- Azienda Ospedaliero Universitaria Consorziale Policlinico - Bari, Bari, Italy
- Istituto Ortopedico Rizzoli, Bologna, Italy
- A.O. Universitaria Meyer, Florence, Italy
- Istituto Giannina Gaslini, Genova, Italy
- FONDAZIONE IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- Azienda Ospedaliera Universitaria "Federico Ii" ., Naples, Italy
- Azienda Ospedaliera di Padova, Padua, Italy
- Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
- Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I, Roma, Italy
- Ospedale Pediatrico Bambin Gesu', Roma, Italy
- Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology, Torino, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02063022 on ClinicalTrials.gov